A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
51 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Novartis Investigative Site
Albury, New South Wales, Australia
Recruiting - Novartis Investigative Site
Parramatta, New South Wales, Australia
Recruiting - Novartis Investigative Site
Strathfield, New South Wales, Australia
Recruiting - Novartis Investigative Site
East Melbourne, Victoria, Australia
Recruiting
- Novartis Investigative Site
Sofia, Bulgaria
Recruiting
- Novartis Investigative Site
London, Ontario, Canada
Recruiting - Novartis Investigative Site
Ottawa, Ontario, Canada
Recruiting
- Novartis Investigative Site
Prague, Czechia
Recruiting - Novartis Investigative Site
Prague, Czechia
Recruiting
- Novartis Investigative Site
Lyon, Rhone, France
Recruiting - Novartis Investigative Site
Créteil, France
Recruiting - Novartis Investigative Site
Dijon, France
Recruiting - Novartis Investigative Site
Paris, France
Recruiting
- Novartis Investigative Site
Bonn, Germany
Recruiting - Novartis Investigative Site
Ludwigshafen, Germany
Recruiting - Novartis Investigative Site
Münster, Germany
Recruiting - Novartis Investigative Site
Tübingen, Germany
Recruiting
- Novartis Investigative Site
Pécs, Baranya, Hungary
Recruiting - Novartis Investigative Site
Debrecen, Hajdu Bihar Megye, Hungary
Recruiting - Novartis Investigative Site
Budapest, Hungary
Recruiting
- Novartis Investigative Site
Florence, FI, Italy
Recruiting - Novartis Investigative Site
Milan, MI, Italy
Recruiting - Novartis Investigative Site
Milan, MI, Italy
Recruiting - Novartis Investigative Site
Roma, RM, Italy
Recruiting
- Novartis Investigative Site
Bunkyo Ku, Tokyo, Japan
Recruiting
- Novartis Investigative Site
Bydgoszcz, Kuyavian-Pomeranian Voivodeship, Poland
Recruiting - Novartis Investigative Site
Krakow, Poland
Recruiting
- Emanuelli Research and Development Center Llc
Arecibo, Puerto Rico
Andres Emanuelli AnzalottaRecruiting
- Novartis Investigative Site
Cluj-Napoca, Cluj, Romania
Recruiting - Novartis Investigative Site
Bucharest, Romania
Recruiting
- Novartis Investigative Site
Santiago Compostela, A Coruna, Spain
Recruiting - Novartis Investigative Site
Sant Cugat Del V, Barcelona, Spain
Recruiting - Novartis Investigative Site
Burjassot, Valencia, Spain
Recruiting - Novartis Investigative Site
Córdoba, Spain
Recruiting
- Novartis Investigative Site
Bristol, United Kingdom
Recruiting - Novartis Investigative Site
London, United Kingdom
Recruiting
- Salehi Retina Institute
Huntington Beach, California, United States
Hani Salehi-HadRecruiting - Retinal Consultants Medical Group Inc
Sacramento, California, United States
Margaret ChangRecruiting - California Retina Consultants
Santa Barbara, California, United States
Dante PieramiciRecruiting - Advanced Research Llc
Boynton Beach, Florida, United States
Drew Philip BawcombeRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 9 Mar 2026
- Primary completion
- 21 Aug 2029
- Completion
- 22 Aug 2029
- Last update posted
- 9 Jul 2026
- Registered enrollment
- 272
- Registry id
- NCT07441642
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.